Spotlight: First study to compare two ketamine therapies for patients with severe depression

"Findings indicate that individual psilocybin-assisted therapy has the potential for beneficial effects on mood and personality characteristics. Moreover, the study highlights the importance of subjective experiences and demographic factors in moderating this effect."

"Based on the currently available comparative evidence, which is almost entirely observational, IV ketamine and IN esketamine show comparable acute response and remission rates, though IV ketamine may act faster."

Dissociative-psychedelic model offers a compassionate, pragmatic, theoretically grounded approach to relieving psychological & existential suffering in palliative care

Evidence suggests that "IV racemic ketamine is more effective than IN esketamine in TRD; convergent preclinical and clinical findings support the hypothesis that arketamine plays a key role in this superiority and that ketamine’s antidepressant mechanisms extend beyond simple NMDAR antagonism."

"...evidence suggests that the use of serotonergic and non-serotonergic psychedelics (ketamine) for the treatment of SUD may provide advantages over traditional therapeutics, and these compounds may eventually become part of the next generation of treatments for SUD under specific circumstances."

"...mystical experiences were strongly related to immediate and sustained psychiatric benefits at the group level and on an individual, session-by-session basis across the six doses, providing mechanistic support for ketamine-psychotherapy pairings."